| abstract |
A suspension formulation of an insulinotropic peptide (eg, glucagon-like peptide 1 (GLP-1) or exenatide) is described and described. The suspension formulation includes (i) a non-aqueous, single phase vehicle, which includes one or more polymers and one or more solvents, the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation that includes the insulinotropic peptide, which the Peptide is dispersed in the vehicle. The particle formulation further includes a stabilizing component that includes one or more stabilizers, for example, carbohydrates, antioxidants, amino acids, and amygotes. Devices for supplying suspension formulations and methods of use are also described. |